NCT06806826

The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study

Evaluatıon of the Effectıveness of Omalızumab Treatment In Patıents Wıth Allergıc Rhınıtıs

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Yuzuncu Yil University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

We aimed to evaluate the usability and efficacy of omalizumab in allergic rhinitis and its potential as an alternative treatment option.

Detailed description

The study was conducted to determine the effectiveness of omalizumab on symptoms in patients diagnosed with allergic rhinitis and to compare it with current medical treatment options.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Omalizumab	The patients in the study group were started on omalizumab and intranasal fluticasone propionate. Omalizumab was administered subcutaneously to these patients at a dose of 300 mg once a month. . Twenty-five patients in the control group were started on intranasal fluticasone propionate spray and a tablet containing 5 mg desloratadine+10 mg montelukast sodium at the same dose and in the same manner as the patients in the study group. The patients were asked to use 100 mg of suspension equivalent to 50 micrograms of fluticasone propionate as two sprays into each nostril once daily and to use the tablet once daily. Patients in both groups were asked to fill out the visual analog scale and their total Ig E levels were checked. Patients who were called for a check-up after eight to ten weeks were evaluated again with the visual analog scale.

Timeline

• Start date: 2019-01-01
• Primary completion: 2020-01-01
• Completion: 2020-03-01
• First posted: 2025-02-04
• Last updated: 2025-02-04

Locations

1 site across 1 country: Turkey (Türkiye)